Results 131 to 140 of about 15,465 (199)

Pronounced benefits of JAK inhibition with baricitinib in COVID-19 pneumonia in obese but not lean subjects

RMD Open
Objective Obesity and age are strongly linked to severe COVID-19 pneumonia where immunomodulatory agents including Janus kinase inhibitors have shown benefits but the efficacy of such therapy in viral pneumonia is not well understood.
Abdulla Watad, Dennis G McGonagle, Howard Amital, Tom Macleod, Or Hen, Paula David, Niv Ben-Shabbat   +6 more
doaj   +1 more source

Oral lichenoid lesions in CTLA‐4 haploinsufficiency: Targeting IFN‐γ‐driven mucosal immunopathology

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 10, Page e864-e867, October 2026.
Chen Wang, Laurie Brenchley, Teresa Greenwell‐Wild, Vasileios Ionas Theofilou, Timothy G. Myers, Chi A. Ma, Katherine Howe, Stefania Pittaluga, Steven M. Holland, Niki M. Moutsopoulos, David Fraser, Gulbu Uzel   +11 more
wiley   +1 more source

OX40–OX40L Structural Insights Applied to Rocatinlimab in Atopic Dermatitis With Alopecia Areata Overlap: Mechanistic Hypotheses and Hair Regrowth

Journal of Cosmetic Dermatology, Volume 25, Issue 10, October 2026.
Waqar Iqbal Khan, Zerwah Zernab Malik, Zia Ullah, Zain Ul Abedeen, Kashmala Ali Yousafzai   +4 more
wiley   +1 more source

Investigation on new solid forms of baricitinib

Dissertação de Mestrado em Química apresentada à Faculdade de Ciências e TecnologiaCurrently, active pharmaceutical ingredient (API) administration is commonly achieved through solid formulations such as tablets and capsules, due to the stability and ...
Silva, Maria Inês Gomes da
core  

The Efficacy and Safety of Baricitinib in the Treatment of Alopecia Areata [PDF]

Introduction: Alopecia Areata (AA) is an autoimmune disorder that causes inflammatory circular, coin-shaped patches of hair loss on the scalp and other body parts.
Sharkawy, Ireny
core  

Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study

, 2020
Baricitinib, an oral Janus kinase (JAK) 1-2 inhibitor, is currently used along biologic DMARDs (bDMARDs) after the failure of methotrexate (MTX) in rheumatoid arthritis (RA).
Riva, Marta, Birra, Domenico, De Vita, Salvatore, Viapiana, Ombretta, Luciano, Nicoletta, Quartuccio, Luca, Bazzani, Chiara, Canziani, Lorenzo Maria, Pozzi, Maria Rosa, Guidelli, Giacomo Maria, Chimenti, Maria Sole, Perricone, Roberto, De Santis, Maria, Selmi, Carlo, Boffini, Nicola, Bianchi, Gerolamo, Frediani, Bruno, Limonta, Massimiliano, Conticini, Edoardo, Gorla, Roberto, Moscato, Paolo, Bruschi, Eleonora, Rossini, Maurizio, Dagna, Lorenzo   +23 more
core  

Baricitinib for refractory chronic graft-versus-host disease: results of a phase 1/2 study. [PDF]

Blood Adv
Holtzman NG, Im A, Curtis L, Schulz E, Sharma R, Pirsl F, Berman A, Ostojic A, Magone de Quadros Costa MT, Cowen EW, Mays J, Comis LE, Joe G, Peer C, Figg W, Rose J, El Jurdi N, Pouzolles M, Hakim F, Taylor N, Pavletic SZ.   +20 more
europepmc   +1 more source

Tissue calcinosis in dermatomyositis - potential role of combination therapy with JAK inhibitors. Case report and literature review. [PDF]

Front Immunol
Janiak P, Smoleńska Ż, Wardowska A, Chmielewski M.   +3 more
europepmc   +1 more source

Shuffling the JAKs: playing a new card in chronic GVHD. [PDF]

Blood Adv
Boiko JR, Carpenter PA.
europepmc   +1 more source

Disease flares with baricitinib dose reductions and development of flare criteria in patients with CANDLE/PRAAS [PDF]

OBJECTIVES: Patients with chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature/proteasome-associated autoinflammatory syndrome (CANDLE/PRAAS) respond to the janus kinase inhibitor 1/2 inhibition with baricitinib at ...
Reinhardt, Adam, de Jesus, Adriana A, Berkun, Yackov, Brogan, Paul A, Robles, Maria, Rastegar, Andre, Goldbach-Mansky, Raphaela, Materne, Grace, Murias, Sara, Ortega-Villa, Ana M, Sanchez, Gina A Montealegre, Schalm, Susanne, Gedik, Kader Cetin   +12 more
core